Table 4.

Projected Net Costs per QALY of 5-year LDL Lowering With High-Intensity Statin-Based Regimens Compared to no LDL Lowering in CKD

	Simvastatin plus Ezetimibe: UK £1.19/daya	High-Intensityb Statins
UK £0.60-£1.10/dayc	UK £0.05-£0.10/dayc
By 5-year risk of CVD at start of treatment
<10%	£39,600	£30,900-£36,300	£17,300-£18,100
10%-<20%	£30,500	£24,800-£28,400	£15,800-£16,300
≥20%	£33,300	£25,300-£30,200	£12,700-£13,400
By CKD stage at start of treatment
3d	£13,000	£9,100-£11,500	£3,100-£3,400
4	£22,400	£18,000-£20,800	£11,100-£11,500
5e	£43,300	£33,400-£39,500	£17,900-£18,800
On dialysis	£42,700	£34,000-£39,400	£20,100-£20,900

Note: Costs and outcomes discounted at 3.5% per annum.

Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; LDL, low-density lipoprotein; QALY, quality-adjusted life-year.

^aBased on 20 mg simvastatin, 10 mg ezetimibe.

^bAchieving ≥40% reductions in LDL cholesterol level.

^cSee Table S2 for high-intensity statin-based regimens in the United Kingdom in this cost range.

^d83% of participants in this category with CKD stage 3b (estimated glomerular filtration rate of 30-<45 mL/min/1.73 m²).

^eNot on dialysis therapy.